SEARCH

SEARCH BY CITATION

References

  • 1
    Evans AA, Chen G, Ross EA, Shen FM, Lin WY, London WT. Eight-year follow-up of the 90,000-person Haimen city cohort: I. Hepatocellular carcinoma mortality, risk factors, and gender differences. Cancer Epidemiol Biomarkers Prev 2002; 11: 369376.
  • 2
    Park KS, Kim H, Kim NG, Cho SY, Choi KH, Seong JK, Paik YK. Proteomics analysis and molecular characterization of tissue ferritin light chain in hepatocellular carcinoma. HEPATOLOGY 2002; 35: 14591466.
  • 3
    Gelatti U, Donato F, Tagger A, Fantoni C, Portolani N, Ribero ML, Martelli C, et al. Etiology of hepatocellular carcinoma influences clinical and pathologic features but not patient survival. Am J Gastroenterol 2003; 98: 907914.
    Direct Link:
  • 4
    Miller RH, Kaneko S, Chung CT, Girones R, Purcell RH. Compact organization of the hepatitis B virus genome. HEPATOLOGY 1989; 9: 322327.
  • 5
    Kim KH, Seong BL. Pro-apoptotic function of HBV X protein is mediated by interaction with c-FLIP and enhancement of death-inducing signal. EMBO J 2003; 22: 21042116.
  • 6
    Bouchard MJ, Wang LH, Schneider RJ. Calcium signaling by HBx protein in hepatitis B virus DNA replication. Science 2001; 294: 23762378.
  • 7
    Chisari FV, Klopchin K, Moriyama T, Pasquinelli C, Dunsford HA, Sell S, Pinkert CA, et al. Molecular pathogenesis of hepatocellular carcinoma in hepatitis B virus transgenic mice. Cell 1989; 59: 11451159.
  • 8
    Kim CM, Koike K, Saito I, Miyamura T, Jay G. HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature 1991; 351: 317320.
  • 9
    Babinet C, Farza H, Morello D, Hadchouel M, Pourcel C. Specific expression of hepatitis B surface antigen (HBsAg) in transgenic mice. Science 1985; 230: 11601163.
  • 10
    Koike K, Moriya K, Iino S, Yotsuyanagi H, Endo Y, Miyamura T, Kurokawa K. High-level expression of hepatitis B virus HBx gene and hepatocarcinogenesis in transgenic mice. HEPATOLOGY 1994; 19: 810819.
  • 11
    Gan RB, Chu MJ, Shen LP, Qian SW, Li ZP. The complete nucleotide sequence of the cloned DNA of hepatitis B virus subtype adr in pADR-1. Sci Sin (Series B) 1987; 30: 507521.
  • 12
    Yang X, Li C, Xu X, Deng C. The tumor suppressor SMAD4/DPC4 is essential for epiblast proliferation and mesoderm induction in mice. Proc Natl Acad Sci U S A 1998; 95: 36673672.
  • 13
    Deng C, Zhang P, Harper JW, Elledge SJ, Leder P. Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 1995; 82: 675684.
  • 14
    Deng C, Wynshaw-Boris A, Zhou F, Kuo A, Leder P. Fibroblast growth factor receptor 3 is a negative regulator of bone growth. Cell 1996; 84: 911921.
  • 15
    Castaldo G, Calcagno G, Sibillo R, Cuomo R, Nardone G, Castellano L, Del Vecchio Blanco C, et al. Quantitative analysis of aldolase A mRNA in liver discriminates between hepatocellular carcinoma and cirrhosis. Clin Chem 2000; 46: 901906.
  • 16
    Ota T, Suto S, Katayama H, Han ZB, Suzuki F, Maeda M, Tanino M, et al. Increased mitotic phosphorylation of histone H3 attributable to AIM-1/Aurora-B overexpression contributes to chromosome number instability. Cancer Res 2002; 62: 51685177.
  • 17
    Shuda M, Kondoh N, Tanaka K, Ryo A, Wakatsuki T, Hada A, Goseki N, et al. Enhanced expression of translation factor mRNAs in hepatocellular carcinoma. Anticancer Research 2000; 20: 24892494.
  • 18
    Kuper H, Mantzoros C, Lagiou P, Tzonou A, Tamimi R, Mucci L, Benetou V, et al. Estrogen, testosterone and sex hormone binding globulin in relation to liver cancer in man. Oncology 2001; 60: 355360.
  • 19
    Villa E, Moles A, Ferretti I, Buttafoco P, Grottola A, Del Buono M, De Santis M, et al. Natural history of inoperable hepatocellular carcinoma: estrogen receptors' status in the tumor is the strongest prognostic factor for survival. HEPATOLOGY 2000; 32: 233238.
  • 20
    Milich DR, Jones JE, Hughes JL, Maruyama T, Price J, Melhado I, Jirik F. Extrathymic expression of the intracellular hepatitis B core antigen results in T cell tolerance in transgenic mice. J Immunol 1994; 152: 455466.
  • 21
    Guidotti LG, Matzke B, Schaller H, Chisari FV. High-level hepatitis B virus replication in transgenic mice. J Virol 1995; 63: 61586169.
  • 22
    Nakamoto Y, Guidotti LG, Kuhlen CV, Fowler P, Chisari FV. Immune pathogenesis of hepatocellular carcinoma. J Exp Med 1998; 188: 341350.
  • 23
    Martin-Caballero J, Flores JM, Garcia-Palencia P, Serrano M. Tumor susceptibility of P21 Waf1/Cip1-deficient mice. Cancer Res 2001; 61: 62346238.
  • 24
    Qiao L, Leach K, McKinstry R, Yacoub A, Park JS, Grant S, Hylemon PB et al. Hepatitis B virus X protein increases expression of p21Cip-1/WAF1/MAD6 and p27Kip-1 in primary mouse hepatocytes, leading to reduced cell cycle progession. HEPATOLOGY 2001; 34: 906917.
  • 25
    Tralhao JG, Roudier J, Morosan S, Giannini C, Tu H, Goulenok C, Carnot F, et al. Paracrine in vivo inhibitory effects of hepatitis B virus X protein (HBx) on liver cell proliferation: an alterative mechanism of HBx-related pathogenesis. Proc Natl Acad Sci U S A 2002; 99: 69916996.
  • 26
    Terradillos O, de La Coste A, Pollicino T, Neuveut C, Sitterlin D, Lecoeur H, Gougeon ML, et al. The hepatitis B virus X protein abrogates Bcl-2-mediated protection against Fas apoptosis in the liver. Oncogene 2002; 21: 377386.
  • 27
    Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA. Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci U S A 1996; 93: 59255930.
  • 28
    Nilsson S, Makela S, Treuter E, Tujague M, Thomsen J, Andersson G, Enmark E, et al. Mechanisms of estrogen action. Physiol Rev 2001; 81: 15351565.
  • 29
    Takano N, Iizuka N, Hazama S, Yoshino S, Tangoku A, Oka M. Expression of estrogen receptor-alpha and -beta mRNAs in human gastric cancer. Cancer Lett 2002; 176: 129135.
  • 30
    Tremblay A, Tremblay GB, Labrie F, Giguere V. Ligand-independent recruitment of SRC-1 to estrogen receptor beta through phosphorylation of activation function AF-1. Mol Cell 1999; 3: 513519.
  • 31
    Chow P, Kiat TC, Choo TB, Machin D. Tamoxifen in hepatocellular carcinoma. Lancet 1998; 352: 819820.
  • 32
    Chow PK, Tai BC, Tan CK, Machin D, Win KM, Johnson PJ, Soo KC, et al. High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: a multicenter randomized controlled trial. HEPATOLOGY 2002; 36: 12211226.